Cancer vaccine using mRNA succeeded in late-stage melanoma trial, Moderna and Merck say
A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other parts of the body in a late-stage clinical trial, the drugmakers Merck and Moderna announced Wednesday,